News

We are pleased to announce that we have signed a collaboration agreement with FRONTEO, Inc. (Head office: Minato-ku, Tokyo; President & Representative Director: Masahiro Morimoto) to use their Drug Discovery AI Factory (DDIAF) to explore new target molecules and indications for our glyco-somatostatin drug candidate (GT-02037).

This agreement aims to create new value in glycan technology, primarily by expanding the indications for glyco-somatostatin (GT-02037). Through the synergistic combination of both companies’ technologies and expertise, we seek to contribute to the development of new pharmaceuticals and the advancement of healthcare, including addressing unmet medical needs.

GlyTech, Inc. signs agreement with FRONTEO, Inc. to explore indications of glyco-somatostatin (GT-02037) using Drug Discovery AI Factory.（PDF.361KB）

We are pleased to announce that the investigator-led clinical trial titled “Early Phase II, Randomized, Open-Label, Crossover, Single-Dose Study to evaluate the effect of GT-02037 subcutaneous formulation on blood levels of Growth Hormone and its Safety compared to Octreotide subcutaneous formulation in Japanese patients with Acromegaly” conducted at Okayama University Hospital has now achieved its enrollment target and the final report has been completed. The results of this clinical trial will be presented by Okayama University Hospital at academic conferences and other venues in the near future.

Clinical trial details: Japan Registry of Clinical Trials

We are pleased to announce that we have signed a Marketing Agreement and a Materials Transfer Agreement with OBI Pharma, Inc. (Head office: Taipei, Taiwan; CEO: Dr. Heidi Wang) with the aims of reaching potential customers in Japan and advancing glycan production.

• GlyTech, Inc. Enters Collaboration with OBI Pharma on GlycOBI® Outreach in Japan and Advancing Glycan Production(PDF, 807KB)